OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by OPKO Health, Inc. on July 1, 2019. The report details a meeting of the Compensation Committee of the Board of Directors held on the same date to review compensation matters for executive officers and non-executive employees.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
The primary material event reported is the grant of stock options to four named executive officers. The options vest ratably over four years and expire on the tenth anniversary of the grant date. The specific grants are as follows:
- Phillip Frost, M.D. (Chairman/Chief Executive Officer): 350,000 stock options
- Jane H. Hsiao, Ph.D. (Vice Chairman/Chief Technical Officer): 350,000 stock options
- Steven D. Rubin (Executive Vice President): 250,000 stock options
- Adam Logal (Senior Vice President/Chief Financial Officer): 250,000 stock options
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares authorized for issuance under the company's equity incentive plan to ensure these grants are covered.
- Confirm the strike price of the granted options, which is not explicitly stated in this summary text.
- Review the vesting schedule details to understand the retention timeline for the named executives.
- Check subsequent filings for the impact of these grants on the company's diluted share count and stock-based compensation expenses.